CMS seeks comments on measure for antipsychotic drug use

The Centers for Medicare & Medicaid Services (CMS) is seeking comments on a proposed hospital quality measure for antipsychotic use in older patients in the inpatient setting.

CMS has contracted with Mathematica Policy Research to develop, electronically specify and maintain process and structural clinical quality measures for CMS hospital quality programs, according to the notice. The contract name is Hospital Inpatient and Outpatient Process and Structural Measure Development and Maintenance.  

The goal of this project is to develop electronic clinical quality measures (eCQMs) for use by providers in CMS quality reporting programs. In conjunction with developing new eCQMs, the project is also tasked to re-engineer existing chart- or claims-based measures as eCQMs.

"We aim to understand the scope of antipsychotic use, the potential for quality improvement opportunities, and the possible unintended consequences of implementing an antipsychotic measure in the acute inpatient hospital setting," the notice reads.

Stakeholders can submit comments until May 15.

Click here for more information.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.